Literature DB >> 31668116

Serum neurofilament levels correlate with retinal nerve fiber layer thinning in multiple sclerosis.

Gabriel Bsteh1, Klaus Berek2, Harald Hegen2, Barbara Teuchner3, Arabella Buchmann4, Margarete M Voortman4, Michael Auer2, Sebastian Wurth2, Anne Zinganell2, Franziska Di Pauli2, Florian Deisenhammer2, Michael Khalil4, Thomas Berger5.   

Abstract

BACKGROUND: Serum neurofilament light chain (sNfL) levels and peripapillary retinal nerve fiber layer (pRNFL) are both emerging biomarkers of neuro-axonal damage in multiple sclerosis (MS). However, data on the relation between sNfL and pRNFL are scarce.
OBJECTIVE: We aimed to determine the relation of sNfL levels with pRNFL thinning in a large cohort of relapsing-remitting (RR) MS patients.
METHODS: We identified 80 patients from a prospective, 3-year observational study on retinal changes in RRMS with annual blood samples available. sNfL levels were measured using single-molecule array (SimoaTM) assay. Annualized loss of pRNFL (aLpRNFL) was determined by individual linear regression models. Correlations between single and repeated sNfL levels and aLpRNFL were analyzed using multivariate linear regression and mixed-effect models.
RESULTS: After correction for sex, age, and baseline sNfL, an sNfL increase of 10 pg/mL was associated with an aLpRNFL of -0.7 µm (95% confidence interval (CI): (-1.3, -0.2), p < 0.001). Patients with ⩾2 sNfL measurements >75th percentile displayed higher aLpRNFL (2.2 µm, standard deviation (SD) 0.6) compared to patients with no sNfL measure >75th percentile (0.4 µm, SD 0.2, p < 0.001). Between 15% and 20% of the aLpRNFL variance could be predicted from sNfL levels.
CONCLUSION: sNfL levels contribute to the prediction of retinal thinning in patients with RRMS, strengthening its value as a biomarker of neuro-axonal damage.

Entities:  

Keywords:  Multiple sclerosis; biomarker; neurofilament; optical coherence tomography; peripapillary retinal nerve fiber layer

Year:  2019        PMID: 31668116     DOI: 10.1177/1352458519882279

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  15 in total

1.  Serum neurofilament light chain and optical coherence tomography measures in MS: A longitudinal study.

Authors:  Eleonora Tavazzi; Dejan Jakimovski; Jens Kuhle; Jesper Hagemeier; Osman Ozel; Murali Ramanathan; Christian Barro; Niels Bergsland; Davorka Tomic; Harald Kropshofer; David Leppert; Zuzanna Michalak; Norah Lincoff; Michael G Dwyer; Ralph H B Benedict; Bianca Weinstock-Guttman; Robert Zivadinov
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2020-05-18

2.  Explorative study of emerging blood biomarkers in progressive multiple sclerosis (EmBioProMS): Design of a prospective observational multicentre pilot study.

Authors:  Ahmed Abdelhak; Andre Huss; Alexander Stahmann; Makbule Senel; Markus Krumbholz; Markus C Kowarik; Joachim Havla; Tania Kümpfel; Ingo Kleiter; Isabella Wüstinger; Uwe K Zettl; Margit Schwartz; Romy Roesler; Tim Friede; Albert C Ludolph; Ulf Ziemann; Hayrettin Tumani
Journal:  Contemp Clin Trials Commun       Date:  2020-05-19

3.  Analysis of Brain Injury Biomarker Neurofilament Light and Neurodevelopmental Outcomes and Retinopathy of Prematurity Among Preterm Infants.

Authors:  Ulrika Sjöbom; William Hellström; Chatarina Löfqvist; Anders K Nilsson; Gerd Holmström; Ingrid Hansen Pupp; David Ley; Kaj Blennow; Henrik Zetterberg; Karin Sävman; Ann Hellström
Journal:  JAMA Netw Open       Date:  2021-04-01

4.  Serum neurofilament levels reflect outer retinal layer changes in multiple sclerosis.

Authors:  Caspar B Seitz; Falk Steffen; Muthuraman Muthuraman; Timo Uphaus; Julia Krämer; Sven G Meuth; Philipp Albrecht; Sergiu Groppa; Frauke Zipp; Stefan Bittner; Vinzenz Fleischer
Journal:  Ther Adv Neurol Disord       Date:  2021-05-25       Impact factor: 6.570

5.  Iron Rims in Patients With Multiple Sclerosis as Neurodegenerative Marker? A 7-Tesla Magnetic Resonance Study.

Authors:  A Dal-Bianco; R Schranzer; G Grabner; M Lanzinger; S Kolbrink; G Pusswald; P Altmann; M Ponleitner; M Weber; B Kornek; K Zebenholzer; C Schmied; T Berger; H Lassmann; S Trattnig; S Hametner; F Leutmezer; P Rommer
Journal:  Front Neurol       Date:  2021-12-21       Impact factor: 4.003

6.  Seven day pre-analytical stability of serum and plasma neurofilament light chain.

Authors:  Patrick Altmann; Markus Ponleitner; Paulus Stefan Rommer; Helmuth Haslacher; Patrick Mucher; Fritz Leutmezer; Axel Petzold; Christoph Wotawa; Rupert Lanzenberger; Thomas Berger; Henrik Zetterberg; Gabriel Bsteh
Journal:  Sci Rep       Date:  2021-05-26       Impact factor: 4.996

Review 7.  Case for a new corticosteroid treatment trial in optic neuritis: review of updated evidence.

Authors:  Axel Petzold; Tasanee Braithwaite; Bob W van Oosten; Lisanne Balk; Elena H Martinez-Lapiscina; Russell Wheeler; Nils Wiegerinck; Christiaan Waters; Gordon T Plant
Journal:  J Neurol Neurosurg Psychiatry       Date:  2019-11-18       Impact factor: 10.154

8.  Serum neurofilament light chain withstands delayed freezing and repeated thawing.

Authors:  Patrick Altmann; Fritz Leutmezer; Heidemarie Zach; Raphael Wurm; Miranda Stattmann; Markus Ponleitner; Axel Petzold; Henrik Zetterberg; Thomas Berger; Paulus Rommer; Gabriel Bsteh
Journal:  Sci Rep       Date:  2020-11-17       Impact factor: 4.379

9.  Increased Serum Neurofilament Light and Thin Ganglion Cell-Inner Plexiform Layer Are Additive Risk Factors for Disease Activity in Early Multiple Sclerosis.

Authors:  Ting-Yi Lin; Viktoriya Vitkova; Susanna Asseyer; Ivette Martorell Serra; Seyedamirhosein Motamedi; Claudia Chien; Marc Ditzhaus; Athina Papadopoulou; Pascal Benkert; Jens Kuhle; Judith Bellmann-Strobl; Klemens Ruprecht; Friedemann Paul; Alexander U Brandt; Hanna G Zimmermann
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2021-08-04

Review 10.  The potential of serum neurofilament as biomarker for multiple sclerosis.

Authors:  Stefan Bittner; Jiwon Oh; Eva Kubala Havrdová; Mar Tintoré; Frauke Zipp
Journal:  Brain       Date:  2021-11-29       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.